CRPC-free survival, serious genitourinary event-free survival, prostate cancer-specific survival, time to next skeletal-related event, PSA response rate, prognostic study of serum PSA 6–8 months after initiation of therapy, time to pain progression, time to chemotherapy for CRPC, QoL, change in BMD, correlation of biomarkers with outcomes, event rate per 100 PY of treatment, toxicity. This evidence concerns the gene KLK3 and prostate carcinoma.